These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 15905894)
21. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Labarrere CA; Zaloga GP Am J Med; 2004 Oct; 117(7):499-507. PubMed ID: 15464707 [TBL] [Abstract][Full Text] [Related]
22. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. van Vonderen MG; Hassink EA; van Agtmael MA; Stehouwer CD; Danner SA; Reiss P; Smulders Y J Infect Dis; 2009 Apr; 199(8):1186-94. PubMed ID: 19275490 [TBL] [Abstract][Full Text] [Related]
23. Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs. de Haro Miralles J; Martínez-Aguilar E; Florez A; Varela C; Bleda S; Acin F Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):107-12. PubMed ID: 19376804 [TBL] [Abstract][Full Text] [Related]
24. The relationship of gamma-glutamyltransferase to C-reactive protein and arterial stiffness. Saijo Y; Utsugi M; Yoshioka E; Horikawa N; Sato T; Gong Y; Kishi R Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):211-9. PubMed ID: 17412574 [TBL] [Abstract][Full Text] [Related]
26. Inflammation in the vascular wall as an early event in atherosclerosis. Prescott SM; Zimmerman GA; McIntyre TM; Stafforini DM Diabetologia; 1997 Jul; 40 Suppl 2():S111-2. PubMed ID: 9248712 [No Abstract] [Full Text] [Related]
27. C-reactive protein in hypertension: clinical significance and predictive value. Schillaci G; Pirro M Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):500-8. PubMed ID: 16979884 [TBL] [Abstract][Full Text] [Related]
28. Association of adiponectin with procollagen type I carboxyterminal propeptide in non-diabetic essential hypertension. Tsai WC; Lin CC; Chen JY; Huang YY; Lee CH; Li WT; Weng CM; Chen JH Blood Press; 2008; 17(4):233-8. PubMed ID: 18671144 [TBL] [Abstract][Full Text] [Related]
29. Is systemic inflammation responsible for pulmonary hypertension in COPD? Sin DD; Man SF Chest; 2006 Aug; 130(2):310-2. PubMed ID: 16899824 [No Abstract] [Full Text] [Related]
30. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. González AS; Guerrero DB; Soto MB; Díaz SP; Martinez-Olmos M; Vidal O Eur J Clin Nutr; 2006 Jun; 60(6):802-9. PubMed ID: 16493453 [TBL] [Abstract][Full Text] [Related]
31. [Present insights in the cerebral small vessel disease physiopathology: the role of C-reactive protein]. Di Napoli M; Papa F Recenti Prog Med; 2006 May; 97(5):246-56. PubMed ID: 16838555 [TBL] [Abstract][Full Text] [Related]
32. Inflammation in atherosclerosis and implications for therapy. Paoletti R; Gotto AM; Hajjar DP Circulation; 2004 Jun; 109(23 Suppl 1):III20-6. PubMed ID: 15198962 [TBL] [Abstract][Full Text] [Related]
33. Atherosclerotic plaque burden, plaque vulnerability and arterial remodeling: the role of inflammation. Vink A; Pasterkamp G Minerva Cardioangiol; 2002 Apr; 50(2):75-83. PubMed ID: 12032461 [TBL] [Abstract][Full Text] [Related]
34. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Schiano V; Laurenzano E; Brevetti G; De Maio JI; Lanero S; Scopacasa F; Chiariello M Clin Nutr; 2008 Apr; 27(2):241-7. PubMed ID: 18237823 [TBL] [Abstract][Full Text] [Related]
35. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Tzoulaki I; Murray GD; Price JF; Smith FB; Lee AJ; Rumley A; Lowe GD; Fowkes FG Am J Epidemiol; 2006 Feb; 163(4):334-41. PubMed ID: 16357107 [TBL] [Abstract][Full Text] [Related]
36. Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nelson CL; Karschimkus CS; Dragicevic G; Packham DK; Wilson AM; O'Neal D; Becker GJ; Best JD; Jenkins AJ Nephrol Dial Transplant; 2005 Nov; 20(11):2420-6. PubMed ID: 16115854 [TBL] [Abstract][Full Text] [Related]
37. Targeting the arterial wall, but what is the target? Shantsila E; Lim HS J Hum Hypertens; 2009 Jan; 23(1):1-3. PubMed ID: 18509342 [No Abstract] [Full Text] [Related]
38. Human urotensin II as a link between hypertension and coronary artery disease. Watanabe T; Kanome T; Miyazaki A; Katagiri T Hypertens Res; 2006 Jun; 29(6):375-87. PubMed ID: 16940699 [TBL] [Abstract][Full Text] [Related]
39. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459 [TBL] [Abstract][Full Text] [Related]
40. Letter by Struthers et al regarding article, "cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function". Struthers AD; Lang CC Circulation; 2006 Sep; 114(10):e383; author reply e384. PubMed ID: 16952991 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]